Foundation Medicine, Inc. Announces Release Of Molecular Information From FoundationCORE To The National Cancer Institute In Support Of The National Cancer Moonshot And Precision Medicine Initiatives

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) announced today that the company will release approximately 18,000 genomic profiles of adult cancers from its FoundationCORE^™ knowledgebase to the National Cancer Institute’s (NCI) Genomic Data Commons portal (GDC). This contribution of de-identified and HIPPA-compliant genomics information represents the largest public data release of its kind to the NCI, more than doubling the size of the NCI’s GDC database. The genomics information is being contributed in an effort to facilitate increased collaboration and accelerate research in precision medicine with the goal of advancing patient care. The announcement was made today to coincide with Cancer Moonshot summits being held across the country.

“We’re honored to participate in this important global effort to transform patient care and to be the first commercial entity to contribute data to the NCI’s GDC, which we believe underscores the quality, integrity and richness of the genomics information contained in FoundationCORE”

“This major infusion of data in the GDC will greatly enhance our ability to use this tool to explore genetic abnormalities in cancer,” said Douglas Lowy, M.D., NCI Acting Director. “Through TCGA and TARGET, we had already established a strong cancer genomic foundation for the GDC at its launch, but with the addition of the genomic data from Foundation Medicine, we believe that the GDC will be an even more useful resource for researchers worldwide to help us unravel the complexities of many forms of cancer.”

Run by the NCI, a part of the National Institute of Health (NIH), the GDC is a new unified data system to facilitate sharing of genomic and clinical data among researchers. It was launched earlier this month as a core component of the National Cancer Moonshot and the Precision Medicine Initiative. FoundationCORE is one of the largest and most robust knowledgebases, containing comprehensive genomic information and insights from more than 80,000 real-world clinical cases. FoundationCORE continuously evolves over time, informed by every new tumor profiled with the company’s clinical assays, FoundationOne^®, FoundationOne^® Heme and FoundationACT^™.

“We’re honored to participate in this important global effort to transform patient care and to be the first commercial entity to contribute data to the NCI’s GDC, which we believe underscores the quality, integrity and richness of the genomics information contained in FoundationCORE,” said Vincent Miller, M.D., chief medical officer, Foundation Medicine. “The amount of genomics information within FoundationCORE has reached unparalleled scale. The insights gleaned from this data release will be instrumental in accelerating research and development efforts for targeted agents and immunotherapies.”

This collaboration with the NCI marks the second public release of information from FoundationCORE this year. In February, Foundation Medicine announced the first ever public release of its pediatric data to stimulate research and development of precision therapies to fight cancer in children. The data set has received a substantial number of inquiries from around the world since the information was made available for research use.

Foundation Medicine is participating in local Cancer Moonshot summits being held across the country today, including at Fox Chase Cancer Center in Philadelphia, PA and Tufts Medical Center, in Boston, MA.

About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine^®, FoundationOne^® and FoundationOne^® Heme are registered trademarks of Foundation Medicine, Inc. FoundationCORE™ and FoundationACT™ are trademarks of Foundation Medicine, Inc.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Foundation Medicine’s anticipated release of genomic data and the ability of genomic data from FoundationCORE to accelerate cancer research and drug development. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that the release of genomic data by Foundation Medicine may not occur in the manner anticipated, may be delayed or may not occur at all; the data may not be as robust as anticipated; the release of this data or the use of the GDC generally does not generate or accelerate research and development activities; and the risks described under the caption “Risk Factors” in Foundation Medicine’s Annual Report on Form 10-K for the year ended December 31, 2015, which is on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.